February 22, 2017
The Proteus Discover digital health system uses an ingestible sensor embedded in a pill to record data about – among other things – patients’ medication adherence. The sensor sends data to an adhesive patch, which in turn sends it to a mobile device. But what are the use cases that require that kind of precision and reliability?
For the Children’s Health, a system of pediatric hospitals in the...
August 22, 2016
Proteus Digital Health is working with Children's Health in Dallas, Texas in one of the first trials of its ingestible sensor technology in pediatric patients, The Dallas Morning News reports.
The trial involves patients recovering from an organ transplant, a group that typically needs to take a lot of medications on a fairly strict schedule. Fifteen patients are using the Proteus platform now...
May 12, 2016
April was a big month for digital health funding, with 15 more deals coming through, totalling an impressive $220 million and bringing the total funding so far this year to $691 million. As we did in February with Oscar, we're excluding the largest deal, Bright Health's $80 million round, from the total because the company in question is a tech-saavy payer, but not a digital health company per se...
April 27, 2016
The FDA declined to approve what would have been the first mass market drug to incorporate Proteus Digital Health's ingestible sensor. The drug, a collaboration between Proteus and Otsuka Pharmaceuticals, combines the Proteus system with the antipsychotic pharmaceutical Abilify.
“While we are disappointed in the FDA’s decision not to approve this digital medicine at this time, both Otsuka and...
April 15, 2016
Redwood City, California-based digital medicine company Proteus Digital Health has raised $50 million from undisclosed investors. The company’s existing investors include Medtronic, Itochu, St. Jude Medical, and Kaiser Permanente Ventures. This brings the company’s total funding to at least $450 million.
The Proteus digital medicine platform, called Proteus Discover, is a medication management...
April 4, 2016
Proteus Digital Health announced interim study results from a randomized control study of its Proteus Discover timed with the American College of Cardiology event, ACC.16, in Chicago this week. The study included 96 patients with uncontrolled hypertension and type 2 diabetes and showed that a majority of the patients using the digital offering achieved the blood pressure target at week four.
January 12, 2016
When Proteus Digital Health got its first FDA clearance, Stephen Colbert, then still the host of The Colbert Report, featured the pill on his ‘Cheating Death’ segment.
“The sensor can help patients suffering from diseases of the central nervous center, including schizophrenia,” he said. “Because nothing is more reassuring to a schizophrenic than a corporation inserting sensors into your body that...
January 11, 2016
Redwood City, California-based Proteus Digital Health announced its first US healthcare provider customer, Barton Health, which will prescribe the company's Proteus Discover to patients. The company says this is the first time its technology has been implemented outside of a clinical trial setting in the US.
Barton Health, a health system in Lake Tahoe, California, will use the medication...
September 10, 2015
After years of using its digital health feedback system in clinical trials and studies, Proteus Digital Health, and partner Otsuka Pharmaceuticals, are poised to launch the first mass market drug to incorporate Proteus's ingestible sensor. The companies have submitted a sensor-embedded version of the antidepressant Abilify for FDA approval.
“Today, patients suffering from severe mental illnesses...
July 2, 2015
Proteus Digital Health has received an update to its FDA 510(k) clearance for its digital medicine platform, adding a new indication to the clearance. The system is now, to the company’s knowledge, the first technology to have an indication in its FDA clearance for measuring medication adherence.
“We are delighted that our collaborative work with the FDA continues to enable positive progress,”...